An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Roche

Status and phase: Active, not recruiting; Phase 4

Conditions: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms

Treatments: Drug: Bevacizumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT01932125

ML28446

Details and patient eligibility

About

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

Enrollment: 100 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice

Exclusion criteria

• Not eligible for treatment with bevacizumab according to the local prescribing information

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Cohort

Experimental group

Treatment:

Drug: Bevacizumab